Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study

BACKGROUND: Carboplatin/paclitaxel is the chemotherapy of choice for advanced ovarian cancer, both in first line and in platinum-sensitive recurrence. Although a significant proportion of patients have some neurotoxicity during treatment, the long-term outcome of chemotherapy-induced neuropathy has...

Descripción completa

Detalles Bibliográficos
Autores principales: Pignata, Sandro, De Placido, Sabino, Biamonte, Rosalbino, Scambia, Giovanni, Di Vagno, Giovanni, Colucci, Giuseppe, Febbraro, Antonio, Marinaccio, Marco, Vernaglia Lombardi, Alessandra, Manzione, Luigi, Cartenì, Giacomo, Nardi, Mario, Danese, Saverio, Valerio, Maria Rosaria, de Matteis, Andrea, Massidda, Bruno, Gasparini, Giampietro, Di Maio, Massimo, Pisano, Carmela, Perrone, Francesco
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1361775/
https://www.ncbi.nlm.nih.gov/pubmed/16398939
http://dx.doi.org/10.1186/1471-2407-6-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1361775/
https://www.ncbi.nlm.nih.gov/pubmed/16398939
http://dx.doi.org/10.1186/1471-2407-6-5

Ejemplares similares